Abstract Library

#1532 Epidemiology, Pathological Features and Clinical Outcome of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)

Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs coordinated by the scientific multidisciplinary Spanish society GETNE, that covers 57 academic and community sites representing all regions of Spain.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Jimenez-Fonseca P, Capdevila J, Alonso Orduña V, Fernández Medina I, Teule Vega A,

Keywords: Neuroendocrine tumor, registry, Spain, survival,

#1526 Therapeutic Strategies in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)

Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs launched by GETNE in 2001.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nuñez B

Authors: Nuñez B, Castaño A, Teule Vega A, Marazuela Azpíroz M, Medina K,

Keywords: NET, surgery, somatostatin analogues, chemotherapy, targeted therapy, survival,

#709 Temozolomide and Capecitabine: An Effective Combination in Metastasic G2 NETs

Introduction: Treatment of neuroendocrine tumors (NETs) with chemotherapy has been validated in different studies. Recently a retrospective trial demonstrated high and durable response rate with Temozolomide and Capecitabine in 30 pancreatic NETs (pNETs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Barrio M, García R, Garcia E, Medina K, Arbeloa B,

Keywords: neuroendocrine, temozolomide, capecitabine,